We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,339.00
Bid: 1,339.00
Ask: 1,339.20
Change: -0.60 (-0.04%)
Spread: 0.20 (0.01%)
Open: 1,342.20
High: 1,352.60
Low: 1,336.20
Yest. Close: 1,339.60
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK and Sanofi in talks to supply 300m vaccine doses to EU

Mon, 3rd Aug 2020 07:43

(Sharecast News) - GlaxoSmithKline and Sanofi said they were in advanced talks with the European Commission to supply up to 300m doses of a Covid-19 vaccine
The companies said the vaccine candidate was developed by Sanofi in partnership with GSK and is based on Sanofi technology used to produce an influenza vaccine and GSK's adjuvant technology.

The doses would be produced in European countries such as France, Belgium, Germany and Italy with regulatory approval possible in the first half of 2021. The companies' statement confirmed an announcement by the commission on Friday.

Roger Connor, president of GSK Vaccines, said: "GSK is proud to be working in partnership with Sanofi to make this vaccine available as soon as possible in Europe. Both companies have significant R&D and manufacturing capability in Europe and are already working hard to scale up production across our networks. This announcement from the EC supports our ongoing efforts."

The British and French drug companies signed a deal with the US government on Friday for Washington to provide $2.1bn to speed up development and manufacturing of the vaccine.

Sanofi expects a Phase 1/2 study of the vaccine to start in September with a Phase 3 study by the end of 2020. If results are positive the vaccine could receive regulatory approval by the first half of 2021, the companies said. GSK and Sanofi are planning to produce more than 1bn doses a year and make the vaccine available globally.



More News

CureVac says well on track to request vaccine approval as planned

* Says infections rate within trial population is high* Some doses aimed for production in '21 to be delivered in '22* Trial result will also offer unique view on spread of variantsBy Ludwig BurgerFRANKFURT, May 5 (Reuters) - Germany's CureVac is ...

5 May 21 15:54

UK prosecutor ends investigation into Airbus individuals - sources

By Kirstin RidleyLONDON, May 4 (Reuters) - Britain's Serious Fraud Office (SFO) has ended a criminal investigation into individuals associated with Airbus, the European planemaker that agreed to a record $4.0 billion global settlement 16 months ag...

4 May 21 16:34

GSK's ViiV says HIV drug gets rolling probe from US watchdog

GSK's ViiV says HIV drug gets rolling probe from US watchdog

4 May 21 14:29

Sunday newspaper round-up: GlaxoSmithKline, Rare Earths, Amazon

(Sharecast News) - Top investors in Glaxo Smith Kline are piling pressure on Dame Emma Walmsley after the activist New York hedge fund Elliott Management was revealed to have built a significant stake. Two top-20 investors in the drugs and consumer goods giant said that the chief executive's future was in doubt after four years of disappointing performance. One top-20 investor said there was "no desire to protect her" among institutional shareholders. Another said that Walmsley, 51, should step aside after her plan to break the business in two is carried out and hand over to her lieutenant, Luke Miels. - Sunday Times

2 May 21 12:32

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

30 Apr 21 12:13

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

30 Apr 21 09:43

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

28 Apr 21 17:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

28 Apr 21 16:06

TOP NEWS: GSK reports first quarter revenue drop amid Covid-19 impact

TOP NEWS: GSK reports first quarter revenue drop amid Covid-19 impact

28 Apr 21 12:40

GSK sticks to guidance after crisis hits profit and revenue

(Sharecast News) - GlaxoSmithKline stuck to its annual guidance after the Covid-19 crisis caused profit and revenue to fall in the first quarter of 2021.

28 Apr 21 12:23

UPDATE 1-GSK exceeds earnings expectations despite sales falling short

(Adds details on earnings, outlook)April 28 (Reuters) - GSK topped analysts' expectations for first-quarter earnings as more people visited clinics for critical treatments such as HIV and routine shots once COVID-19 curbs eased, adding on Wednesda...

28 Apr 21 12:20

UPDATE 2-GSK focused on split as COVID curb easing helps earnings

(Recasts, adds details, CEO quote)By Pushkala Aripaka and Ludwig BurgerApril 28 (Reuters) - GSK confirmed plans to split in two were "well underway" on Wednesday after exceeding analysts' first-quarter earnings forecasts as an easing of COVID-19 cu...

28 Apr 21 12:20

UPDATE 3-GSK pursuing split as easing of COVID curbs aids earnings

(Adds details, analyst reaction)By Pushkala Aripaka and Ludwig BurgerApril 28 (Reuters) - Plans for GlaxoSmithKline to split in two are "well underway" it said on Wednesday after exceeding first-quarter earnings forecasts as an easing of COVID-19 ...

28 Apr 21 12:20

UPDATE 4-GSK focused on split as cost checks, COVID-19 easings aid earnings

* CEO says focused on seeing split through, big picture* COVID-19 pandemic still taking toll on overall business* GSK expects recovery in vaccine sales in H2* Shares marginally higher following Q1 results release (Adds details on sales, analyst comm...

28 Apr 21 12:20

GSK beats profit expectations, to detail separation plan in June

April 28 (Reuters) - GSK topped analysts' expectations for first-quarter earnings as more people visited clinics for routine shots once COVID-19 curbs eased, adding on Wednesday that plans to split into two were "well underway" with details expec...

28 Apr 21 12:05

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.